131 related articles for article (PubMed ID: 20394535)
1. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.
Palamà IE; Leporatti S; de Luca E; Di Renzo N; Maffia M; Gambacorti-Passerini C; Rinaldi R; Gigli G; Cingolani R; Coluccia AM
Nanomedicine (Lond); 2010 Apr; 5(3):419-31. PubMed ID: 20394535
[TBL] [Abstract][Full Text] [Related]
2. Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
Palamà IE; Coluccia AM; Gigli G
Nanomedicine (Lond); 2014 Jul; 9(14):2087-98. PubMed ID: 24364873
[TBL] [Abstract][Full Text] [Related]
3. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
4. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Holtz MS; Forman SJ; Bhatia R
Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
8. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
[TBL] [Abstract][Full Text] [Related]
11. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
12. Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
Giallongo C; La Cava P; Tibullo D; Parrinello N; Barbagallo I; Del Fabro V; Stagno F; Conticello C; Romano A; Chiarenza A; Palumbo GA; Di Raimondo F
Eur J Haematol; 2011 Mar; 86(3):216-25. PubMed ID: 21198861
[TBL] [Abstract][Full Text] [Related]
13. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
14. Influence of charge on encapsulation and release behavior of small molecules in self-assembled layer-by-layer microcapsules.
Mandapalli PK; Labala S; Vanamala D; Koranglekar MP; Sakimalla LA; Venuganti VV
Drug Deliv; 2014 Dec; 21(8):605-14. PubMed ID: 24328418
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
16. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
17. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Faber E; Nausová J; Jarosová M; Egorin MJ; Holzerová M; Rozmanová S; Maresová I; Divoký V; Indrák K
Leuk Lymphoma; 2006 Jun; 47(6):1082-90. PubMed ID: 16840200
[TBL] [Abstract][Full Text] [Related]
18. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Orsolic N; Golemovic M; Quintás-Cardama A; Scappini B; Manshouri T; Chandra J; Basic I; Giles F; Kantarjian H; Verstovsek S
Cancer Sci; 2006 Sep; 97(9):952-60. PubMed ID: 16822295
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Aloisi A; Di Gregorio S; Stagno F; Guglielmo P; Mannino F; Sormani MP; Bruzzi P; Gambacorti-Passerini C; Saglio G; Venuta S; Giustolisi R; Messina A; Vigneri P
Blood; 2006 Feb; 107(4):1591-8. PubMed ID: 16249386
[TBL] [Abstract][Full Text] [Related]
20. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]